laboratory shelfs with bottles and vials

Life Sciences & Healthcare

Germany

The CMS Life Sciences und Healthcare Sector Group is made up of over 50 lawyers across Europe, many of whom have specialised in the Life Sciences und Healthcare industry for several years.

The essence of the group's approach is teamwork, working closely as colleagues in Western and Central Europe. The group has complementary expertise in pharmaceutical, biotechnology, medical device, diagnostic and related areas, so can offer pan-European and local, national advice and assistance to the Life Sciences und Healthcare industries.

The group is recognised as having centres of excellence in respect of pharmaceuticals and medical devices in its practices in the United Kingdom, the Netherlands and Germany as well as specialist tax expertise in France.

Services

The CMS Life Sciences und Healthcare Sector Group provides the following comprehensive range of services:

  • Regulatory
  • Pre-clinical and clinical research
  • Collaboration and licensing
  • Financing/M&A stock option schemes
  • Business restructuring
  • Strategic alliances, mergers and acquisitions
  • Distribution and parallel import issues
  • Patent protection and enforcement
  • Branding, trade dress, advertising and labelling
  • Media issues
  • Personal data
  • Product liability and litigation
  • Health and safety
  • EC & competition/competition enforcement
  • Public sector tendering
  • Environment
  • Immigration

Contact

For further information on CMS Life Sciences und Healthcare Sector Group please contact Mr. Jens Wagner.

We are strategic partners of

Young Excellence in Healthcare (YEH) is an interdisciplinary network bringing together young professionals from the healthcare sector. It seeks to develop an intelligent framework for delivering health services in the world of tomorrow. CMS Germany advises YEH strategically and exclusively on all legal matters. CMS also acts as a sounding board for the legal issues and healthcare policies YEH wishes to promote.

Read more Read less

Law Firm of the Year for Healthcare

JUVE Guide, 2018/2019

Choose area

    Care Market

    As the population in Germany ages, care and retirement homes are one of the fastest-growing sectors in the country. As such, they are attracting increasing attention from investors. A major factor here is that demand for care services is largely independent of the economic cycle. The high potential for consolidation in the sector is also a powerful driver: investment in social welfare facilities offers attractive prospects.

    Read more

    Healthcare

    The healthcare sector in Germany is heavily regulated, shaped by a number of very different interests and, above all, subject to constant change. Demographic change is an additional factor – an aging population is increasing the demand for medical services. Players in the healthcare market need to take advantage of existing opportunities, minimise the risks and avoid undesirable developments.

    Read more

    Feed

    Show only
    Marite Aragaki
    Dec 2018
    CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
    27/03/2019
    Judg­ment on Ab­rax­is C-443/17; 21st March 2019
    The CJEU de­livered its judg­ment last week on the case of Ab­rax­is v Comp­troller Gen­er­al of Pat­ents con­cern­ing Sup­ple­ment­ary Pro­tec­tion Cer­ti­fic­ates (SPCs) for new for­mu­la­tions of medi­cin­al products. The Court has ruled that Art­icle 3(d) of Reg­u­la­tion No 469/2009,.
    26/10/2018
    Re­cog­nised with JUVE Award 2018: CMS Ger­many named...
    25/01/2018
    European Com­mis­sion as­sesses ad­equacy of Gen­er­al Food Law in food...
    In an eval­u­ation of the EU le­gis­lat­ive frame­work for the 2002 Gen­er­al Food Law Reg­u­la­tion (GFLR), the European Com­mis­sion has found that this frame­work ap­pears to ad­dress most cur­rent trends, such as growth, com­pet­it­ive­ness and in­creased glob­al­isa­tion, but.
    Dr. Stefan Voß
    25/10/2018
    CMS again ad­vises Bel­gian real es­tate in­vestor Cofin­immo...
    28/11/2017
    REACH and Brexit – Some clar­ity gained but more cer­tainty re­quired
    Sev­en­teen months after the UK Ref­er­en­dum on wheth­er to re­main in or leave the EU a num­ber of areas re­main un­cer­tain for busi­ness.   For the chem­ic­als in­dustry[i] whose products form an in­teg­ral part of our daily lives, the status of the corner­stone of the chem­ic­als.
    19/10/2018
    CMS ad­vises Chart In­dus­tries on di­vestit­ure of its...
    06/11/2017
    Brexit: State of play for Life Sci­ences com­pan­ies
    With the UK pre­par­ing to leave the European Uni­on (EU) on 30 March 2019, life sci­ences com­pan­ies are plan­ning ahead for changes to the busi­ness and reg­u­lat­ory en­vir­on­ment. Dis­cus­sions at the EU Sum­mit on 19 Oc­to­ber 2017 primar­ily fo­cused on what are re­garded.
    Sep 2018
    Di­git­isa­tion in health­care: From uto­pia to real­ity...
    #law­volu­tion
    30/08/2017
    The leg­al and reg­u­lat­ory chal­lenges of get­ting a bi­osim­il­ar product...
    After a pharma view on bi­osim­il­ars was provided in the pre­vi­ous Ex­pert View column, a leg­al per­spect­ive is provided by Nick Beck­ett, man­aging part­ner at CMS Beijing and glob­al co-head of the firm­'s lifes­ci­ences sec­tor group.
    10/05/2017
    CMS ad­vises share­hold­ers of mi­cro­scopy spe­cial­ist Lux­endo...
    20/07/2017
    Entry in­to force of EU Clin­ic­al Tri­als Reg­u­la­tion post­poned to 2019
    On 16 June 2017, the European Medi­cines Agency (“EMA”) pub­lished a press re­lease1 an­noun­cing the post­pone­ment of the entry in­to force of the EU Clin­ic­al Tri­als Reg­u­la­tion of 16 April 2016. 2 It was one of the top­ics at the June 2017 meet­ing of the EMA Man­age­ment.